HPLC/MS/MS methodology for sensitive quantitation of monic acid A, the metabolic product of the antibiotic mupirocin

Biomarkers. 2011 Aug;16(5):422-5. doi: 10.3109/1354750X.2011.582153. Epub 2011 May 20.

Abstract

Patients who are treated by self-medication with intranasal mupiricin (Bactroban™) for controlling meticillin-resistant Staphylococcus aureus may, or may not, adhere to their regimen. Herein, we describe a potential methodology for assessing adherence by measuring the gastric degradation product, monic acid A (MA), as a biomarker in urine. MA was isolated (~80% recovery) through a Waters Oasis HLB cartridge and detected (e.g. 25 pg on the column) by HPLC/MS/MS (API4000). Within a calculated 10(6)-fold margin, this analytical sensitivity should facilitate urinary MA quantitation if, for example, 1% of intranasal mupirocin is swallowed and degraded characteristically to MA by gastric acidity.

Publication types

  • Validation Study

MeSH terms

  • Anti-Bacterial Agents / metabolism*
  • Chromatography, High Pressure Liquid / methods*
  • Limit of Detection
  • Mupirocin / metabolism*
  • Pyrans / analysis
  • Pyrans / metabolism
  • Tandem Mass Spectrometry / methods*

Substances

  • Anti-Bacterial Agents
  • Pyrans
  • monic acid A
  • Mupirocin